ArticleCell reports. Medicine2026

A bispecific nanobody-drug conjugate targeting TROP2 and c-Met for low-concentration, single-dose treatment of pancreatic cancer.

Wenjing Ning et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.